Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 30/100

ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation into ADMA Biologics, Inc. on behalf of its stockholders for potential violations of federal securities laws. This follows the unexpected resignation of the company's independent auditor, which resulted in a steep decline of over 20% in the stock price. The firm is encouraging investors to come forward if they have suffered losses or have relevant information regarding these matters. This situation raises concerns about ADMA Biologics' business practices and its impact on shareholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics is being investigated for potential violations of federal securities laws.
  • The resignation of its independent auditor led to a significant decline in stock price.
  • ADMA Biologics shares dropped over 20% after the news was made public.

Full Press Release Details

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ:ADMA) on behalf of ADMA Biologics stockholders. Our investigation concerns whether ADMA Biologics has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you purchased or otherwise acquired ADMA Biologics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the investigation about ADMA Biologics?

The investigation examines potential violations of federal securities laws by ADMA Biologics.

What caused the decline in ADMA Biologics stock?

ADMA Biologics' stock dropped over 20% after the unexpected resignation of its auditor.

Who should contact Bragar Eagel & Squire, P.C.?

Stockholders who lost money or have information about ADMA Biologics should contact them.

What services does Bragar Eagel & Squire, P.C. offer?

The firm represents investors in various complex litigation, including securities cases.

Who are the main contacts for the investigation?

Brandon Walker and Marion Passmore are the attorneys handling the ADMA investigation.

Last updated: Nov 13, 2024